MedTech Short '25: High Val MedTech (view performance)

For high-performing operators within this theme, such as Medpace Holdings (MEDP), expect sustained high single-digit employee growth, a strong focus on retention, and continued low turnover rates. Monitoring for consistent reports of stable or increasing headcount, particularly in strategic growth areas like oncology, would confirm strengthening theme execution. Conversely, a deterioration would be signaled by hiring freezes, significant layoffs, or an inability to attract and retain talent in key therapeutic areas. For structurally challenged companies, which are the primary focus of this short basket, watch for announcements of workforce reductions, hiring slowdowns, or increased investment in AI and automation aimed at cost reduction. Confirmation of the short thesis would come from public announcements of workforce restructuring, declining employee numbers, or increased R&D spend on automation technologies. Deterioration would be indicated by an inability to effectively cut costs through workforce management, leading to persistent margin pressure.

Several second-order trends are emerging within the MedTech landscape that could significantly impact the 'High Val MedTech' theme. Firstly, **AI integration is moving beyond hype to operational impact**, with AI being increasingly integrated into robotic-assisted surgery, predictive monitoring, and diagnostic imaging. This shift could create a further bifurcation in the market, favoring companies that successfully leverage AI for efficiency and improved outcomes, while potentially challenging those with less differentiated technologies. Secondly, the **continued migration of procedures to outpatient and Ambulatory Surgical Center (ASC) settings**, reinforced by CMS policies, is creating opportunities for MedTech companies focused on portable devices, at-home diagnostics, and remote monitoring. This trend could exert pressure on traditional hospital-centric models and benefit agile innovators. Thirdly, **capital market bifurcation** is evident, with overall MedTech M&A remaining active but capital increasingly concentrating in fewer, larger deals for 'quality assets' with durable growth and high return on invested capital (ROIC). Early-stage funding remains constrained, potentially forcing smaller, less differentiated companies to struggle for capital or become acquisition targets at lower valuations, thereby reinforcing the 'high valuation' aspect of the short theme. Fourthly, the new **CMS/FDA RAPID pathway** could significantly shorten the time to Medicare coverage for breakthrough medical devices. While a tailwind for highly innovative MedTech, it could be a headwind for companies with less differentiated or 'substantially similar' technologies that may not qualify or face longer traditional pathways. Lastly, the **shift in new business awards towards oncology** (as seen with Medpace) highlights the continued strength and investment focus in precision oncology and liquid biopsy, potentially at the expense of other therapeutic areas like cardiometabolic.